Press Release



TOHO HOLDINGS CO., LTD. and Shionogi Pharma Co., Ltd. conclude a basic agreement on a business alliance in the active pharmaceutical ingredients business

TOHO HOLDINGS CO., LTD. (headquarters: Setagaya-ku, Tokyo; Chairman and Representative Director: Norio Hamada; President and Representative Director: Atsushi Udoh; "TOHO HOLDINGS" hereinafter) and Shionogi Pharma Co., Ltd. (headquarters: Settsu, Osaka Prefecture; Representative Director and President: Ryuichi Kume; "Shionogi Pharma" hereinafter) have concluded a basic agreement on a business alliance on stable supplies and quality control for active pharmaceutical ingredients.

Against a backdrop of internationalization of logistics networks and their profitability, at present many of the active ingredients used in pharmaceuticals sold in Japan are produced at overseas manufacturing facilities. As a result, the impact of any quality-related issues represents a risks to stable supplies of pharmaceuticals, and securing the procurement of high-quality active ingredients is an urgent and permanent issue.

Through this alliance, the two companies will contribute to the further progress of the Japanese pharmaceuticals industry by developing a platform to contribute to stable supplies of high-quality pharmaceuticals through distribution of high-quality active ingredients, in import of active ingredients from overseas in the case of TOHO HOLDINGS and in manufacturing processes, including the quality of active ingredients and risks of impurities, at Shionogi Pharma.

About Toho Holdings

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

About Shionogi Pharma

Shionogi Pharma began doing business on April 1, 2019, with the mission of being a manufacturer focused on technological development trusted by its customers. In addition to activities for development of production methods and formulas for active pharmaceutical ingredients through commercial production, its structure enables provision of a full range of services including development of analytical methods and support for equipment design utilizing pharmaceutical engineering technologies.